{ "schemaVersion": 2, "eyebrow": "Vascular neurology", "title": "Ischemic Stroke", "summary": "Acute ischemic stroke requires parallel stabilization, hemorrhage-excluding brain imaging, rapid reperfusion eligibility assessment, and vascular imaging for large-vessel occlusion. Intravenous thrombolysis and mechanical thrombectomy are time-sensitive complementary therapies; avoid diagnostic or transfer delays that defer either treatment.", "seoDescription": "Evidence-based acute ischemic stroke evaluation, intravenous thrombolysis, mechanical thrombectomy selection, imaging, monitoring, and secondary prevention.", "clinicalQuestion": "How should physicians rapidly evaluate, reperfuse, monitor, and initiate prevention in adults with suspected acute ischemic stroke?", "specialty": "Vascular Neurology", "audience": "U.S. physicians and medical trainees", "tags": [ "acute ischemic stroke", "stroke thrombolysis", "mechanical thrombectomy", "large-vessel occlusion", "CTA", "NIHSS", "tenecteplase", "alteplase" ], "keyTakeaways": [ "Treat suspected acute ischemic stroke as a time-critical emergency: establish last-known-well time, obtain glucose and noncontrast brain imaging, and assess NIHSS without delaying reperfusion decisions.[2][7]", "Use IV thrombolysis for eligible patients within 4.5 hours; do not delay it for vascular or advanced imaging when thrombolysis eligibility is otherwise established.[2][4]", "Obtain vascular imaging promptly when thrombectomy is possible. For anterior-circulation large-vessel occlusion, thrombectomy plus best medical management improves 90-day functional independence within 6 hours and benefits selected patients through 24 hours.[4]", "For thrombectomy-eligible patients, IV thrombolysis and endovascular therapy are complementary: initiate thrombolysis promptly, but neither therapy should delay the other.[4]", "After acute treatment, admit to a dedicated stroke unit, monitor for neurologic and hemorrhagic complications, establish stroke mechanism, and implement mechanism-directed secondary prevention.[2][6]" ], "sections": [ { "id": "first-hour-priorities", "eyebrow": "Hyperacute care", "heading": "First-hour evaluation and triage", "intro": "Run clinical assessment, exclusion of hemorrhage, and reperfusion planning in parallel.", "paragraphs": [ "The immediate objective is to determine whether the patient has a disabling acute ischemic deficit, exclude intracranial hemorrhage and important mimics, establish time last known well, and identify eligibility for IV thrombolysis and thrombectomy. Use the NIHSS to quantify severity, communicate deficits, and support triage, but do not use a low NIHSS alone to dismiss potentially disabling deficits or large-vessel occlusion.[4][7]", "Perform noncontrast head CT or MRI before specific acute reperfusion therapy. In most U.S. emergency pathways, noncontrast CT provides the essential first imaging information: exclude hemorrhage and assess early ischemic change. Obtain glucose immediately because hypoglycemia can mimic stroke; obtain CBC, coagulation studies, renal function, ECG, and cardiac evaluation in parallel, but do not await coagulation or platelet results before thrombolysis unless anticoagulant exposure, coagulopathy, or thrombocytopenia is suspected.[7]" ], "bullets": [ "Document exact last-known-well time, prestroke functional status, anticoagulant and antiplatelet exposure, recent surgery or bleeding, and baseline blood pressure.[7]", "Maintain airway protection and ventilatory support when impaired consciousness or bulbar dysfunction compromises the airway; administer supplemental oxygen for hypoxemia rather than routinely to nonhypoxemic patients.[7]", "Activate the local stroke and neurointerventional pathway early; EMS prenotification and routing to an appropriate stroke-capable facility reduce downstream delays.[7]" ], "subsections": [], "table": { "caption": "Immediate diagnostic actions in suspected acute ischemic stroke.[7]", "columns": [ "Action", "Decision enabled" ], "rows": [ [ "Focused history, neurologic examination, and NIHSS", "Establish last-known-well time, deficit severity, likely vascular syndrome, mimics, and reperfusion eligibility.[7]" ], [ "Point-of-care glucose and noncontrast CT or MRI", "Correct hypoglycemia if present and exclude hemorrhage before reperfusion therapy.[7]" ], [ "CTA or MRA when thrombectomy is plausible", "Identify treatable large-vessel occlusion and extracranial access anatomy; do not defer eligible early IV thrombolysis for this imaging.[4][7]" ], [ "ECG, cardiac monitoring, CBC, coagulation studies, renal function", "Identify atrial fibrillation, coagulopathy, thrombocytopenia, and medical comorbidity; selective results should not delay thrombolysis.[7]" ] ] } }, { "id": "reperfusion", "eyebrow": "Time-dependent therapy", "heading": "Reperfusion treatment", "intro": "Match therapy to time, imaging, occlusion site, and clinical disability.", "paragraphs": [ "Intravenous thrombolysis remains the standard acute reperfusion treatment when administered early. Alteplase has established benefit when given within 4.5 hours of onset, with treatment effect diminishing as time to treatment increases.[2][6] The supplied older AHA/ASA guideline describes alteplase 0.9 mg/kg IV, maximum 90 mg, with 10% given as a bolus over 1 minute and the remainder infused over 60 minutes.[7] This dose is historical guidance within the supplied evidence; clinicians should verify against current institutional protocol and current AHA/ASA guidance.", "Tenecteplase 0.25 mg/kg IV push was noninferior to standard-dose alteplase in acute ischemic stroke within 4.5 hours in the cited stroke guideline update, including anterior-circulation large-vessel occlusion patients intended for thrombectomy; symptomatic intracranial hemorrhage was similar, and reperfusion outcomes may be better in that bridging setting.[3] Practice recommendations and regulatory details should be confirmed locally because the cited source is not a U.S. guideline.", "Mechanical thrombectomy is standard of care for selected large-vessel occlusion stroke. In pooled randomized trials of anterior-circulation large-vessel occlusion treated within 6 hours, thrombectomy plus best medical management achieved functional independence at 90 days in 47.6% versus 30.9% with medical management alone, with 154 additional independent patients per 1,000 treated.[4]" ], "bullets": [ "For eligible anterior-circulation large-vessel occlusion within 6 hours, offer thrombectomy plus best medical management, including IV thrombolysis when indicated.[4]", "For eligible patients with anterior-circulation large-vessel occlusion 6 to 24 hours from last known well, use advanced imaging selection consistent with DAWN or DEFUSE-3 criteria.[4]", "Do not apply an upper age limit or upper NIHSS cutoff to exclude otherwise appropriate thrombectomy candidates; patients aged 80 years or older benefited in trial meta-analysis.[4]", "If IV thrombolysis is indicated, start it promptly while preparing thrombectomy; IV treatment should not delay thrombectomy, and thrombectomy should not delay IV treatment.[4]", "For low NIHSS large-vessel occlusion, randomized evidence was limited in the cited guideline; thrombectomy may be reasonable for disabling deficits or clinical worsening, ideally within a trial or institutional protocol.[4]" ], "subsections": [ { "heading": "Blood pressure before and after reperfusion", "paragraphs": [ "For patients receiving IV alteplase, blood pressure should be reduced to no more than 185/110 mm Hg before treatment and maintained below 180/105 mm Hg for at least 24 hours after treatment in the cited AHA/ASA guidance.[7] During and for 24 hours after thrombectomy, the ESO-ESMINT guideline suggests keeping blood pressure below 180/105 mm Hg and avoiding intraprocedural systolic blood pressure drops; evidence for a more specific target or preferred antihypertensive drug was very low.[4]" ], "bullets": [] } ], "table": { "caption": "Evidence-based thrombectomy selection principles from randomized-trial era guidance.[4]", "columns": [ "Clinical setting", "Selection and action" ], "rows": [ [ "Anterior-circulation large-vessel occlusion, 0-6 hours", "Proceed rapidly with thrombectomy plus best medical management when there is no evidence of extensive infarct core; examples include ASPECTS ≥6 or core volume ≤70 mL.[4]" ], [ "Anterior-circulation large-vessel occlusion, 6-16 hours", "Thrombectomy is recommended when DEFUSE-3 criteria are met: age ≤90 years, NIHSS ≥6, core <70 mL, penumbra >15 mL, and perfusion-core ratio >1.8.[4]" ], [ "Anterior-circulation large-vessel occlusion, 6-24 hours", "Thrombectomy is recommended when DAWN clinical-core mismatch criteria are met, including age- and NIHSS-stratified core-volume limits.[4]" ], [ "IV-thrombolysis eligible and thrombectomy candidate", "Use bridging IV thrombolysis plus thrombectomy; treat both as early as possible without sequential delay.[4]" ] ] } }, { "id": "post-reperfusion-and-inpatient-care", "eyebrow": "Monitoring", "heading": "Post-reperfusion monitoring and acute inpatient care", "intro": "Prevent physiologic injury, identify complications, and preserve eligibility for subsequent prevention.", "paragraphs": [ "Admit patients to a dedicated stroke unit; specialized stroke-unit care improves survival and functional outcome.[2][7] After IV thrombolysis, perform frequent neurologic and blood-pressure assessments, avoid unnecessary invasive tubes during the first 24 hours, and obtain follow-up brain imaging at 24 hours before starting antiplatelet or anticoagulant therapy according to the cited AHA/ASA protocol.[7]", "Monitor for hemorrhagic transformation, cerebral edema, dysphagia, aspiration, arrhythmia, fever, glucose abnormalities, and venous thromboembolism. Screen swallowing before oral intake. Treat hypoglycemia promptly, avoid hypoxemia, identify and treat fever sources, and use cardiac monitoring during the first 24 hours to detect atrial fibrillation and other clinically significant arrhythmias.[7]", "Routine urgent anticoagulation to prevent early recurrence or neurologic worsening is not recommended in acute ischemic stroke because bleeding risk offsets benefit in the cited evidence.[7] Aspirin was recommended within 24 to 48 hours after stroke onset in the older AHA/ASA guideline, but not within 24 hours of thrombolysis.[7] Current antithrombotic timing and selection should be verified against contemporary guidance, especially after thrombectomy or hemorrhagic transformation." ], "bullets": [ "After thrombectomy, complete reperfusion is the procedural goal when achievable with reasonable safety; TICI 3 reperfusion was associated with greater functional independence and lower mortality and symptomatic intracranial hemorrhage than TICI 2b in observational evidence.[4]", "Use local anesthesia or conscious sedation when feasible, but do not avoid general anesthesia when clinically required; minimize delays and avoid blood-pressure drops.[4]", "Evaluate unexplained deterioration urgently with neurologic reassessment and brain imaging to assess hemorrhage, edema, recurrent ischemia, or procedural complication.[4][7]" ], "subsections": [], "table": { "caption": "Complications requiring active surveillance after ischemic stroke treatment.[4][7]", "columns": [ "Complication", "Monitoring and response" ], "rows": [ [ "Symptomatic intracranial hemorrhage", "Frequent neurologic and blood-pressure assessment; new severe headache, vomiting, acute hypertension, or neurologic decline during alteplase should prompt stopping infusion if ongoing and emergent CT.[7]" ], [ "Cerebral edema or malignant infarction", "Monitor closely during the first days after large hemispheric or cerebellar infarction; transfer or involve neurosurgery when malignant edema risk is present.[7]" ], [ "Aspiration and pneumonia", "Perform swallow assessment before oral intake; protect airway and treat suspected pneumonia promptly.[7]" ], [ "Hyperglycemia or hypoglycemia", "Measure glucose early and repeatedly as clinically indicated; promptly correct hypoglycemia and avoid persistent marked hyperglycemia.[7]" ], [ "Cardiac arrhythmia", "Use at least 24-hour cardiac monitoring to identify atrial fibrillation and clinically important arrhythmias.[7]" ] ] } }, { "id": "etiology-and-secondary-prevention", "eyebrow": "Next decisions", "heading": "Mechanism-directed secondary prevention", "intro": "The acute admission should establish the most likely stroke mechanism and prevention plan.", "paragraphs": [ "Once reperfusion decisions are complete, determine vascular and cardiac mechanisms because secondary prevention is mechanism-dependent. Vascular imaging identifies intracranial and extracranial occlusive disease and access-relevant anatomy; echocardiography and rhythm assessment assess cardioembolic sources. The cited ischemic cerebrovascular disease guideline depicts a cryptogenic-stroke pathway incorporating CTA/MRA, transcranial Doppler, transthoracic or transesophageal echocardiography, and selected catheter angiography or CSF studies when indicated.[3]", "For noncardioembolic minor ischemic stroke or high-risk TIA, short-term dual antiplatelet therapy is an evidence-based strategy in contemporary stroke care, but the supplied U.S. search material does not provide current U.S. agent selection, dose, or duration. Avoid extrapolating the cited Chinese guideline's genotype-directed ticagrelor regimen into U.S. routine care without confirming current U.S. recommendations.[3]", "For atrial fibrillation or another cardioembolic source, long-term oral anticoagulation selection must account for renal function, interactions, valve status, and bleeding risk. Direct oral anticoagulants have lower intracranial hemorrhage risk than warfarin in major nonvalvular AF trials, but severe renal impairment and mechanical valves require different approaches; trial populations excluded severe renal impairment, and dabigatran performed poorly in mechanical heart valves.[11][12]" ], "bullets": [ "Use a high-intensity, mechanism-directed prevention plan after ischemic stroke or TIA; secondary prevention includes antithrombotic therapy, vascular risk-factor treatment, and management of causal carotid, cardiac, or other vascular disease.[2][7]", "For patients with atrial fibrillation, assess renal function serially because direct oral anticoagulant dosing is renal-function dependent; the cited review recommends Cockcroft-Gault creatinine clearance for dosing decisions.[11]", "Avoid combining anticoagulants with antiplatelet agents unless there is a separate compelling indication because combination therapy increases bleeding risk.[11]" ], "subsections": [], "table": { "caption": "Etiologic evaluation domains that alter secondary prevention.[3][7][11]", "columns": [ "Suspected mechanism", "Key evaluation", "Prevention implication" ], "rows": [ [ "Large-artery atherosclerosis", "CTA or MRA of intracranial and extracranial circulation; assess for symptomatic stenosis or tandem lesion.[3][7]", "Antithrombotic strategy and carotid or other vascular intervention depend on lesion severity, anatomy, and timing; acute tandem-lesion stenting strategy remains uncertain.[4]" ], [ "Cardioembolism", "ECG, inpatient rhythm monitoring, and structural cardiac assessment with echocardiography as indicated.[7]", "Atrial fibrillation generally shifts long-term prevention toward anticoagulation, with renal function, bleeding risk, and valve status guiding agent selection.[11][12]" ], [ "Cryptogenic stroke", "Structured evaluation can include CTA/MRA, transcranial Doppler, transthoracic or transesophageal echocardiography, and selected additional tests.[3]", "Do not assume an embolic mechanism without evidence; prevention should follow the documented or most likely cause." ] ] } }, { "id": "practice-gaps", "eyebrow": "Uncertainty", "heading": "Areas requiring individualized decisions", "intro": "Evidence is strongest for early anterior-circulation large-vessel occlusion reperfusion.", "paragraphs": [ "Evidence for thrombectomy is most mature in anterior-circulation large-vessel occlusion. The supplied guideline identifies ongoing uncertainty regarding very low NIHSS scores, extensive infarct core, M2 occlusion, acute tandem cervical carotid lesions, optimal anesthesia, and post-thrombectomy blood-pressure targets.[4]", "In late-window stroke, strict imaging selection improves certainty of benefit, but it also limits generalizability. DAWN and DEFUSE-3 criteria were derived from narrowly selected populations using advanced imaging; patients outside those criteria require expert multidisciplinary review and adherence to current local protocols.[4]", "Older sources in the search results contain historical treatment thresholds and alteplase protocols. Because the search set also identifies a 2026 AHA/ASA acute ischemic stroke guideline but does not provide its full recommendations, clinicians should verify current U.S. guidance and institutional protocols before implementing treatment details.[2][8][9]" ], "bullets": [], "subsections": [], "table": { "caption": "", "columns": [], "rows": [] } } ], "faq": [ { "question": "Should vascular imaging delay IV thrombolysis?", "answer": "No. In otherwise eligible early presenters, vascular imaging should identify thrombectomy candidates but should not delay IV thrombolysis. Begin thrombolysis promptly while activating endovascular treatment when large-vessel occlusion is suspected or confirmed.[4][7]" }, { "question": "Is advanced perfusion imaging required for thrombectomy?", "answer": "For anterior-circulation large-vessel occlusion within 0 to 6 hours, advanced imaging is not necessary for selection in the cited ESO-ESMINT guidance. Beyond 6 hours, advanced imaging matching DAWN or DEFUSE-3 selection is required in that evidence framework.[4]" }, { "question": "Can older adults receive mechanical thrombectomy?", "answer": "Yes. Age 80 years or older should not impose an upper age cutoff for otherwise eligible thrombectomy candidates. Trial meta-analysis showed benefit in older adults within 6 hours, with late-window selection remaining imaging-dependent.[4]" }, { "question": "What is the initial blood-pressure threshold for alteplase?", "answer": "The cited AHA/ASA acute stroke guideline requires blood pressure at or below 185/110 mm Hg before alteplase and below 180/105 mm Hg for at least 24 hours afterward.[7]" } ], "references": [ { "number": 1, "title": "Clinician-Reported Outcomes in Co-Primary Endpoint for Stroke Treatment Device | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/about-fda/division-patient-centered-development/clinician-reported-outcomes-co-primary-endpoint-stroke-treatment-device", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 2, "title": "Ischemic stroke - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/1078", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 3, "title": "Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update | Stroke and Vascular Neurology", "detail": "svn.bmj.com", "url": "https://svn.bmj.com/content/8/6/e3", "authors": "svn.bmj.com", "host": "svn.bmj.com" }, { "number": 4, "title": "European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke | Journal of NeuroInterventional Surgery", "detail": "jnis.bmj.com", "url": "https://jnis.bmj.com/content/15/8/e8", "authors": "jnis.bmj.com", "host": "jnis.bmj.com" }, { "number": 5, "title": "European Stroke Organisation (ESO) and ...", "detail": "jnis.bmj.com", "url": "https://jnis.bmj.com/content/16/9/1", "authors": "jnis.bmj.com", "host": "jnis.bmj.com" }, { "number": 6, "title": "Revolution in acute ischaemic stroke care: a practical guide to mechanical thrombectomy | Practical Neurology", "detail": "pn.bmj.com", "url": "https://pn.bmj.com/content/17/4/252", "authors": "pn.bmj.com", "host": "pn.bmj.com" }, { "number": 7, "title": "Guidelines for the Early Management of Adults With Ischemic Stroke", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/strokeaha.107.181486", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 8, "title": "2026 Guideline for the Early Management of Patients With ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/STR.0000000000000513", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 9, "title": "2026 Acute Ischemic Stroke Guidelines", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/guidelines/acute-ischemic-stroke", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 10, "title": "Highlights of ISC: New Guidelines for Early Management ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/do/10.1161/blog.20260302.923146/full", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 11, "title": "Practical Management of Anticoagulation in Patients With Atrial Fibrillation", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2015.01.049", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 12, "title": "Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2016.06.057", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 13, "title": "2024 ACC Expert Consensus Decision Pathway for ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2023.12.024", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 14, "title": "2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2026.03.056", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 15, "title": "Management of Acute Ischemic Stroke Due to Large ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109719382191", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 16, "title": "based pharmacokinetics modeling to investigate formulation ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12589", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com" }, { "number": 17, "title": "American Society for Clinical Pharmacology and Therapeutics", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3607", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com" }, { "number": 18, "title": "Narrative review of migraine management in patients with ...", "detail": "headachejournal.onlinelibrary.wiley.com", "url": "https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14437", "authors": "headachejournal.onlinelibrary.wiley.com", "host": "headachejournal.onlinelibrary.wiley.com" }, { "number": 19, "title": "Physiologically‐Based Pharmacokinetic Modeling to Support ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70141", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com" }, { "number": 20, "title": "American and European Guideline Comparison for Ischemic Stroke and TIA: Key Points - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/09/18/13/32/comparison-of-american", "authors": "www.acc.org", "host": "www.acc.org" }, { "number": 21, "title": "Guidelines for Early Management of Acute Ischemic Stroke: Key Points - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/11/06/15/31/guidelines-for-the-early-management-of-ais", "authors": "www.acc.org", "host": "www.acc.org" }, { "number": 22, "title": "Stroke Risk Intraplaque Hemorrhage Volume and Ischemic", "detail": "www.ajnr.org", "url": "https://www.ajnr.org/content/early/2025/06/20/ajnr.A8889.full.pdf", "authors": "www.ajnr.org", "host": "www.ajnr.org" }, { "number": 23, "title": "Treatment and Intervention for Stroke", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/stroke/treatment/index.html", "authors": "www.cdc.gov", "host": "www.cdc.gov" }, { "number": 24, "title": "COVID-19 Pandemic and Quality of Care and Outcomes of Acute Stroke Hospitalizations: the Paul Coverdell National Acute Stroke Program", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/pcd/issues/2021/21_0130.htm", "authors": "www.cdc.gov", "host": "www.cdc.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Clinician-Reported Outcomes in Co-Primary Endpoint for Stroke Treatment Device | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/about-fda/division-patient-centered-development/clinician-reported-outcomes-co-primary-endpoint-stroke-treatment-device", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "## Clinical Context\n\nAcute ischemic stroke occurs when the blood supply to part of the brain is reduced or interrupted, resulting in the death of brain cells in that area. Treatment varies depending on time from stroke onset and indications from brain imaging, but it can include medication to dissol", "score": 0.18920664 }, { "number": 2, "title": "Ischemic stroke - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/1078", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Royal College of Physicians\n\nLondon\n\nUK\n\n###### Disclosures\n\nTR declares that he has no competing interests.\n\n##### Peer reviewer acknowledgements\n\nBMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed", "score": 0.6222074 }, { "number": 3, "title": "Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update | Stroke and Vascular Neurology", "detail": "svn.bmj.com", "url": "https://svn.bmj.com/content/8/6/e3", "authors": "svn.bmj.com", "host": "svn.bmj.com", "snippet": "Conclusions This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.\n\n## Highlights\n\nThe clinical management of ischaemic cerebrovascular diseases comprises a total of 287 recommendations, including 136 new recommendations and 15 revised ", "score": 0.6490677 }, { "number": 4, "title": "European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke | Journal of NeuroInterventional Surgery", "detail": "jnis.bmj.com", "url": "https://jnis.bmj.com/content/15/8/e8", "authors": "jnis.bmj.com", "host": "jnis.bmj.com", "snippet": "general anesthesia procedure, whenever possible. Excessive blood pressure drops should be avoided (see PICO question 14).134 Adequate monitoring of vital parameters also of patients under conscious sedation or local anesthesia is advised. [...] Results We found high-quality evidence to recommend MT ", "score": 0.62879556 }, { "number": 5, "title": "European Stroke Organisation (ESO) and ...", "detail": "jnis.bmj.com", "url": "https://jnis.bmj.com/content/16/9/1", "authors": "jnis.bmj.com", "host": "jnis.bmj.com", "snippet": "by D Strbian · 2024 · Cited by 44 — The aim of this ESO-ESMINT Guideline is to provide evidence-based recommendations to assist stroke physicians in their decision-making in the acute management", "score": 0.42105237 }, { "number": 6, "title": "Revolution in acute ischaemic stroke care: a practical guide to mechanical thrombectomy | Practical Neurology", "detail": "pn.bmj.com", "url": "https://pn.bmj.com/content/17/4/252", "authors": "pn.bmj.com", "host": "pn.bmj.com", "snippet": "## \n\n## Introduction\n\nIn the UK, stroke is the most common serious neurological disease (incidence 115–150 per 100 000 population)1 2 and a leading cause of death;3 there are more than 1.2 million stroke survivors,4–7 of whom more than 50% have a disability.8 Improving outcome from stroke is thus a ", "score": 0.3737392 }, { "number": 7, "title": "Guidelines for the Early Management of Adults With Ischemic Stroke", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/strokeaha.107.181486", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "After stabilization of the patient’s condition, rehabilitation, measures to prevent long-term complications, patient and family education, and family support may be started. Some patients may need treatment for depression. In addition, the patient should be evaluated to determine the most likely cau", "score": 0.60666215 }, { "number": 8, "title": "2026 Guideline for the Early Management of Patients With ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/STR.0000000000000513", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "Ischemic strokes account for >80% of all strokes in the United States and >60% of all strokes globally. Stroke is also a leading cause of death", "score": 0.54913354 }, { "number": 9, "title": "2026 Acute Ischemic Stroke Guidelines", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/guidelines/acute-ischemic-stroke", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association.", "score": 0.48718598 }, { "number": 10, "title": "Highlights of ISC: New Guidelines for Early Management ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/do/10.1161/blog.20260302.923146/full", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "The much-anticipated “2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke” was published by the American Heart", "score": 0.41762826 }, { "number": 11, "title": "Practical Management of Anticoagulation in Patients With Atrial Fibrillation", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2015.01.049", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "| Dosing considerations for nonvalvular AF with renal adjustments | If CrCl‡ is 15–30 ml/min: 75 mg twice daily If CrCl is<15 ml/min: avoid use | If CrCl‡ is 15–50 ml/min: 15 mg daily with evening meal | If the patient has at least 2 of the following: - Age≥80 years old - Weight≤60 kg - SCr≥1.5 mg/d", "score": 0.42362547 }, { "number": 12, "title": "Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2016.06.057", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "For patients in the United States, the Food and Drug Administration (FDA) has approved dabigatran, 75 mg twice a day (b.i.d.); rivaroxaban, 15 mg once daily; and apixaban, 2.5 mg b.i.d., for patients with a CrCl of 15 to 29 ml/min. These dosages are not approved on the basis of clinical trial outcom", "score": 0.192646 }, { "number": 13, "title": "2024 ACC Expert Consensus Decision Pathway for ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2023.12.024", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "clinicians.213 Likewise, patients and clinicians need to be cognizant of reordering procedures, which becomes especially important if doses are changed—refills/reorders are not always sent and, unfortunately, refills/reorders cannot be requested before the 60-day postapproval date. This may create a", "score": 0.1515673 }, { "number": 14, "title": "2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2026.03.056", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Drugs that affect the renin-angiotensin-aldosterone system, including RASi, MRA, and SGLT2i, change intrarenal hemodynamics and alter renal electrolyte handling, potentially causing changes in serum creatinine and electrolyte concentrations.43 RASi and MRA-related increases in serum creatinine and s", "score": 0.09726189 }, { "number": 15, "title": "Management of Acute Ischemic Stroke Due to Large ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109719382191", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by JM Ospel · 2020 · Cited by 98 — The only available 2 treatment options are intravenous alteplase and endovascular therapy (mechanical clot removal), both of which are highly", "score": 0.3498664 }, { "number": 16, "title": "based pharmacokinetics modeling to investigate formulation ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12589", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com", "snippet": "by N Farhan · 2021 · Cited by 16 — ischemic stroke reduction. of generic DOACs. ischemic stroke. FDA has published a product- specific guidance for DABE BE, Prescribing", "score": 0.5826579 }, { "number": 17, "title": "American Society for Clinical Pharmacology and Therapeutics", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3607", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com", "snippet": "FDA labels were reviewed for 101 OACs, predict the extent of renal OAT1/OAT3 DDIs. Users can search for publications using generic drug or", "score": 0.15746078 }, { "number": 18, "title": "Narrative review of migraine management in patients with ...", "detail": "headachejournal.onlinelibrary.wiley.com", "url": "https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14437", "authors": "headachejournal.onlinelibrary.wiley.com", "host": "headachejournal.onlinelibrary.wiley.com", "snippet": "Ubrogepant may be used in severe hepatic disease with dose adjustment and lasmiditan can be used in end stage renal disease. Though non-medicine", "score": 0.14512776 }, { "number": 19, "title": "Physiologically‐Based Pharmacokinetic Modeling to Support ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70141", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com", "snippet": "by JWT Yates · 2026 · Cited by 7 — Modeling of renal and hepatic impairment requires ... Most drugs used in the neonatal intensive care unit are not approved by the FDA", "score": 0.1287991 }, { "number": 20, "title": "American and European Guideline Comparison for Ischemic Stroke and TIA: Key Points - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/09/18/13/32/comparison-of-american", "authors": "www.acc.org", "host": "www.acc.org", "snippet": "# \n\n# American and European Guideline Comparison for Ischemic Stroke and TIA: Key Points\n\nThe following are key points to remember from a review article comparing American and European guideline recommendations for diagnostic workup and secondary prevention of ischemic stroke and transient ischemic ", "score": 0.60805947 }, { "number": 21, "title": "Guidelines for Early Management of Acute Ischemic Stroke: Key Points - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/11/06/15/31/guidelines-for-the-early-management-of-ais", "authors": "www.acc.org", "host": "www.acc.org", "snippet": "# \n\n# Guidelines for Early Management of Acute Ischemic Stroke: Key Points\n\nThe following are key points to remember from the 2019 Update to the American Heart Association/American Stroke Association (AHA/ASA) 2018 Guidelines for the\nEarly Management of Acute Ischemic Stroke:\n\nClinical Topics:\nAntic", "score": 0.60750073 }, { "number": 22, "title": "Stroke Risk Intraplaque Hemorrhage Volume and Ischemic", "detail": "www.ajnr.org", "url": "https://www.ajnr.org/content/early/2025/06/20/ajnr.A8889.full.pdf", "authors": "www.ajnr.org", "host": "www.ajnr.org", "snippet": "Specifically, we aimed to identify clinically relevant thresholds of IPH volume that were associated with ischemic symptoms. MATERIALS AND", "score": 0.37072703 }, { "number": 23, "title": "Treatment and Intervention for Stroke", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/stroke/treatment/index.html", "authors": "www.cdc.gov", "host": "www.cdc.gov", "snippet": "Brain scans will show what type of stroke you had. You may also be seen by a neurologist who treats brain disorders, a neurosurgeon who performs surgery on the brain, or a specialist in another area of medicine.\n\n### Treating ischemic stroke\n\nIf you get to the hospital within 3 hours of the first sy", "score": 0.21948004 }, { "number": 24, "title": "COVID-19 Pandemic and Quality of Care and Outcomes of Acute Stroke Hospitalizations: the Paul Coverdell National Acute Stroke Program", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/pcd/issues/2021/21_0130.htm", "authors": "www.cdc.gov", "host": "www.cdc.gov", "snippet": "| Factor | Hemorrhagic Stroke | | | Ischemic Stroke | | | Transient Ischemic Attack | | |\n --- --- --- --- --- |\n| 2019 | 2020 | P Valueb | 2019 | 2020 | P Valueb | 2019 | 2020 | P Valueb |\n| Performance measures established by Paul Coverdell National Acute Stroke Program, % | | | | | | | | | |\n", "score": 0.18772796 } ], "publishedAt": "2026-08-20T23:27:39.608364Z", "updatedAt": "2026-08-20T23:27:39.608364Z", "readingMinutes": 6, "slug": "ischemic-stroke" }